Company intelligence / Profile preview

Pureos Biologics

Küsnacht/Zürich, Switzerland

Ownership: Private
Development stage: Other

Overview

Pureos Bioventures is a venture capital firm with over $205M in committed capital, exclusively investing in private innovative drug development companies. They focus on next-generation biological drugs, nucleic acids, cell and gene therapies across therapeutic areas like oncology, immunology, ophthalmology, rare diseases, and neuroscience. Their portfolio includes 17-20 companies, with notable exits including Araris Biotech and ImCheck Therapeutics.

Modalities: BiologicsNucleic AcidsCell TherapyGene Therapy
Industry: Investors

Partnerships

BaseLaunch (exclusive VC partner)

Beyond the preview

Go deeper on Pureos Biologics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Pureos Biologics.

Explore the full profile